Please ensure Javascript is enabled for purposes of website accessibility

Why Editas Medicine Stock Sank Today

By Keith Speights - Updated Feb 10, 2021 at 4:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors reacted negatively to a major deal announced by Editas' former partner with another gene-editing biotech.

What happened

Shares of Editas Medicine (EDIT -1.18%) sank 11.4% as of the market close on Wednesday. The big decline came after AbbVie (ABBV -1.97%) announced a partnership with privately held Caribou Biosciences to develop chimeric antigen receptor T cell (CAR-T) therapies. 

So what

Why did AbbVie's deal with Caribou cause Editas stock to fall? Probably because the big drugmaker canceled a collaboration with Editas last year to develop a gene-editing therapy. Some investors appear to be viewing AbbVie's new partnership with Caribou as a clear snub of Editas.

DNA with a fragment separated from the main part

Image source: Getty Images.

However, there are a couple of key points to keep in mind. First, Editas originally teamed up with Allergan -- not AbbVie. It was only after AbbVie's acquisition of Allergan in 2020 that the company scrapped its agreement with Editas. Second, the Editas-Allergan partnership focused on a gene-editing therapy targeting a rare eye disease, not a CAR-T therapy. 

In the big scheme of things, the AbbVie-Caribou deal doesn't matter for Editas. What does matter is how the biotech's pipeline candidates fare in clinical testing.

Now what

Editas has begun dosing patients for the safety portion of a phase 1 study evaluating EDIT-301 in treating sickle cell anemia. However, the company must obtain U.S. Food and Drug Administration (FDA) approval for an improved potency assay before it can enroll patients in the efficacy phase of the study. Editas' shares could enjoy a bump when it jumps this hurdle.

Also, Editas expects to report initial results by the end of this year from a phase 1/2 study evaluating EDIT-101 in treating rare genetic eye disease Leber congenital amaurosis 10. If those results are positive, it'll almost certainly provide a major catalyst for the biotech stock

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$10.89 (-1.18%) $0.13
AbbVie Inc. Stock Quote
AbbVie Inc.
$148.03 (-1.97%) $-2.98

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.